CellCentric
Cambridge
About CellCentric
CellCentric is a clinical-stage biotech company focusing on the inhibition of p300/CBP to treat specific cancers, particularly solid tumors. The programme also has potential clinical utility in non-small cell lung, breast, and colon cancer. The company's oral drug, Inobrodib, is currently in Phase I/II clinical trials and aims to address cancers such as multiple myeloma. The company is committed to science-driven solutions for cancer, with a patient-focused approach to novel therapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $255.7M
- Funding stage: Late Stage Venture
- Last round: Series C (May 2025)
- Website: cellcentric.com
- Phone: 44 1799 531 130
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cellcentric-115298 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.